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Abstract
Purpose—Previous studies demonstrated poor response to neoadjuvant systemic therapy (NST) 
for breast cancer among black women and women who are overweight or obese but this may be 
due to chemotherapy under dosing. We assessed associations of race, ethnicity and body mass 
index (BMI) with pathologic complete response (pCR) in clinical trial populations.
Methods—1797 women enrolled in four NST trials (CALGB 40601, 40603; ACOSOG Z1041, 
Z1071) were included. Tumor subtypes were defined by estrogen receptor (ER) and HER2 status. 
Logistic regression generated odds ratios (OR) and 95% confidence intervals (CI) for the 
associations of race, ethnicity, and BMI with pCR adjusting for subtype, study arm, lymph node 
status, tumor size, and tumor grade.
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Results—253 (14.1%) were black, 199 (11.1%) Hispanic, 520 (28.9%) overweight, and 743 
(41.4%) obese. Compared to whites, Blacks and Hispanics were more likely to be obese and 
Blacks were more likely to have triple-negative cancer. pCR rates differed significantly by tumor 
subtype. In multivariate analyses, neither race (black vs. white: OR: 1.18, 95% CI: 0.85–1.62) nor 
ethnicity (Hispanic vs. non-Hispanic: OR: 1.30, 95% CI: 0.67–2.53) were significant predictors of 
pCR overall or by subtype. Overweight and obese women had lower pCR rates in ER+/HER2+, 
but higher pCR rates in ER−/HER2+ cancers.
Conclusions—There was no difference in breast pCR according to race or ethnicity. Overall, 
there was no major difference in pCR rates by BMI. These findings suggest that pCR with 
optimally dosed NST is a function of tumor, rather than patient, biology.
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Introduction
Obesity [1,2], and black race [3,4] have each been independently associated with poor breast 
cancer outcomes. The relationship of Hispanic ethnicity with breast cancer outcomes has 
been inconsistent with some studies suggesting equal or superior outcomes when compared 
to non-Hispanic whites, while others suggest worse outcomes [5,6,3]. Black race, Hispanic 
ethnicity, and obesity are each associated with a higher incidence of more aggressive tumor 
biology (high grade, hormone receptor negative, high proliferation fraction, more 
lymphovascular invasion) [5,7,8]. Differences in tumor subtype likely contribute to observed 
poorer outcomes, but residual disparities remain [9]. This could be due, at least in part, to 
differences in response to therapy [10]. In addition, differences in quality of chemotherapy, 
including treatment delays [11,12] and suboptimal dosing [13] may contribute to disparate 
breast cancer outcomes according to race, ethnicity, and body mass index (BMI). Given the 
high prevalence of overweight and obesity among black and Hispanic women in the US, it is 
possible that race and BMI may interact. In an effort to address these disparities, it is 
important to investigate whether, independent of their measurable tumor characteristics, and 
in a setting of standardized therapeutic regimens, overweight, obesity, or black race are 
associated with response to therapy.
Achievement of a pathologic complete response (pCR) to neoadjuvant systemic therapy 
(NST) can be defined in a number of ways, but all definitions include the absence of residual 
invasive cancer in the breast (in-breast pCR). Some definitions also require the absence of 
invasive and in-situ disease and include the axillary nodes [14]. While the absence of 
invasive and in-situ disease in the breast and the axillary nodes is most strongly associated 
with favorable prognosis [15], in-breast pCR is highly correlated with pCR in the axillary 
nodes [16]. Regardless of definition, pCR rates differ greatly across tumor subtypes with the 
highest rates observed among patients with triple negative or estrogen receptor (ER)-
negative, human epidermal growth factor receptor-2 (HER2)-positive (ER−/HER2+) cancers 
while very low pCR rates are seen in patients with ER+/HER2− tumors [17]. In an era of 
personalized medicine, NST often allows women with locally advanced breast cancer to 
become candidates for breast conserving surgery[18] and permits in vivo assessment of 
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treatment response [19]. Women achieving pCR have better event-free and overall survival 
than those who do not, though this association is also subtype-dependent [15]. The greatest 
survival benefits of pCR appear to occur in patients with triple negative and ER−/HER2+ 
tumors [20]. Because of its demonstrated association with survival, the Food and Drug 
Administration allows pCR to be used as a surrogate endpoint for accelerated approval in 
pharmaceutical trials [21].
Given the observed disparities in survival according to race, ethnicity, and BMI and the 
association of pCR with survival, the purpose of this study was to examine the association of 
race, ethnicity and BMI with pCR in clinical trial populations. Our sample includes multiple 
trials in which chemotherapy dosing, which may vary considerably between patient 
populations outside of trials [22,23], was standardized and rigorously accounted for. Using 
data on 1,797 women participating in four Alliance for Clinical Trials in Oncology 
(Alliance) clinical trials we evaluated the proportion of women achieving in-breast pCR 
according to race, ethnicity, and BMI. We examine these factors overall, and stratified by 
subtypes defined by ER status and HER2.
Methods
Study population
This analysis pools data from four neoadjuvant chemotherapy clinical trials conducted by 
the members of the Alliance (Table 1), Cancer and Leukemia Group B (CALGB) and 
American College of Surgeons Oncology Group (ACOSOG) are now part of the Alliance. 
Two trials (CALGB 40601 and ACOSOG Z1041) were limited to patients with HER2+ 
cancers, while one (CALGB 40603) enrolled only patients with triple-negative cancers [24–
26]. The fourth trial (ACOSOG Z1071) included all breast cancer subtypes of breast cancer; 
it was designed to evaluate the false-negative rate for sentinel lymph node surgery following 
neoadjuvant chemotherapy in women initially presenting with biopsy-proven node-positive 
breast cancer [27]. All trials were approved by the appropriate medical ethics committees. 
All patients gave written informed consent for study participation and data collection.
Data collection and statistical analysis
Data collection and statistical analyses were conducted by the Alliance Statistics and Data 
Center. Race and ethnicity were self-reported and BMI was collected by institutional study 
coordinators from chemotherapy orders. Breast cancer tumor subtypes were assigned on the 
basis of clinical estrogen receptor (ER) and HER2 status as determined locally. ER was 
assessed by standard criteria using immunohistochemical (IHC) staining. HER2 was 
assessed using either IHC or fluorescence in situ hybridization (FISH). Pathologic complete 
response was defined as the absence of residual invasive disease in the breast (ypT0/is). This 
was the primary endpoint for all trials except Z1071, which as noted previously, evaluated a 
nodal question but collected breast and nodal pCR rates on participants.
Analyses included 1797 women from the four trials. We used logistic regression models to 
examine the relationship between race, ethnicity BMI and response to neoadjuvant 
chemotherapy. We evaluated the association between race (Black or White), ethnicity 
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(Hispanic or Non-Hispanic) and BMI (<20, 20–24, 25–29, ≥30 kg/m2) with pCR in the 
breast following NST. We tested for potential interaction between race and BMI using a 
cross product term. We present models overall and stratified by subtypes defined by ER 
status and HER2 (ER+/HER2−, ER+/HER2+, ER−/HER2+, and triple negative). Models are 
adjusted for subtype (overall model only), study arm, lymph node status, and tumor grade. 
Tumor size was not collected in Z1041. We performed a sensitivity analysis by running 
models with and without tumor size included (using a missing indicator). As results did not 
materially differ, we present results without adjustment for tumor size. Statistical tests were 
two-sided, and p < 0.05 was considered significant. Statistical analyses were performed by 
Alliance statisticians at the Alliance Statistics and Data Center using SAS version 9.3 (SAS 
Institute, Cary, NC) on a dataset frozen on January 13, 2016.
Results
Patient Characteristics (Table 2)
Of the 1797 women included in analyses, 1177 (83.1%) were white, 253 (14.1%) were 
black, 127 (7.1%) were listed as ‘other’, 199 (11.1%) were Hispanic, and 520 (28.9%) were 
overweight (BMI 25–29) and 743 (41.3%) were obese (BMI ≥ 30 kg/m2). Information on 
ER, PR, and HER2 status was available for 1784 (99.3 %) patients. The mean age of 
overweight and obese women (50.5 years) was higher than for normal weight women (47.4 
years) (p <0.0001). Compared to white women, a higher percentage of black women had 
triple-negative cancers (49.8% vs. 34.1%), with consequent reductions in the percentage of 
black women with ER+ and HER2+ cancers (p=0.0001). A slightly higher percentage of 
black women had clinically node-positive disease at study entry (24.9%, vs. 18.8% for white 
women; p=0.05). Compared to white women, black women had a higher mean BMI (31.9 
kg/m2 vs. 29.1 kg/m2; p <0.0001) and were more likely to be obese (60.1% vs. 38.9%; p 
<0.0001). Hispanic women were also more likely to be obese than non-Hispanic women 
(49.2% vs. 41.2%; p=0.0003). Aside from a slight increase in the percentage of patients with 
triple-negative cancers who were obese (43.8% vs. 40.2% for other subtypes), there were no 
major differences in the distribution of BMI among the subtypes (p=0.68).
pCR rates, Race, Ethnicity (Tables 3 & 4)
Overall, the pCR rate was significantly higher in patients with ER+/HER2+ (38.1%; OR: 
2.16, 95% CI: 1.32–3.51), ER−/HER2+ (62.7%; 5.48: 3.40–8.85) and triple-negative 
(46.6%; 2.56: 1.75–3.75) cancers than in patients with ER+/HER2− cancers (15.9%). In 
total, 40.4% (99/245) of black women achieved pCR as compared to 39.8% (550/1381) of 
white women. Adjusting for subtype and other potential confounders, we observed no 
significant association between black race and pCR (OR: 1.18, 95% CI: 0.85–1.62). In 
analyses stratified by tumor subtype, we also saw no significant differences in pCR rates 
between black and white women (Table 4). Hispanic ethnicity was also not associated with 
pCR, either overall (Table 3) or when stratified by tumor subtype (Table 4). Overall, 46.4% 
(90/194) of Hispanic women achieved pCR compared to 39.6% (570/1441) of non-Hispanic 
women. Adjusting for subtype and other potential confounders, we found no significant 
association between Hispanic ethnicity and pCR (OR: 1.22, 95% CI 0.86–1.72). In analyses 
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stratified by tumor subtype, we also saw no significant differences in pCR rates between 
Hispanic and non-Hispanic women (Table 4).
BMI and pCR (Tables 3 & 4)
Compared to normal weight women (BMI 20–24), in whom the overall pCR rate was 43.6%, 
the small cohort (n= 66, 3.7% of the study population) of underweight women (BMI <20) 
had a non-significantly higher pCR rate of 51.6% (OR 1.60: 95% CI 0.89–2.86), while 
overweight (38.8%; OR 0.86: 0.64–1.16) and obese (38.4%; OR 0.82: 0.62–1.08) had non-
significantly lower pCR rates. In multivariable adjusted models, there was a statistically non-
significant, inverse association between BMI and pCR (p-trend=0.09; Table 4). In adjusted 
models there was a significant inverse association between BMI and pCR in ER+/HER2+ 
patients (p-trend=0.01); in this subtype, overweight and obese women had pCR rates of 
25.9% (30/116) and 39.4% (61/155) compared to 47.7% (52/109) and 47.4% (9/19) for 
normal and underweight women, respectively. In contrast, in ER−/HER2+ patients pCR 
rates were higher in overweight (71.3%; 62/87), obese women (60.7%; 74/122) and 
underweight women (83.3%; 10/12) women compared to normal weight women (54.4%; 
49/90), resulting in a non-significant positive association between BMI and pCR (p-
trend=0.82) for that subtype. We saw no significant differences in pCR rates according to 
BMI among women with ER+/HER2− or triple negative tumors. There was no interaction 
between race and BMI (p=0.91).
Discussion
In this large pooled analysis of four randomized clinical trials including 1797 patients, we 
examined whether race, Hispanic ethnicity and/or BMI were associated with in-breast 
pathologic complete response to neoadjuvant chemotherapy and HER2−targeted therapy in 
patients with HER2+ cancers. We observed no difference in pCR rates according to race or 
ethnicity overall or when stratified by tumor subtype. We observed no overall differences 
according to BMI, but did see trends associating increasing BMI with lower pCR rates in ER
+/HER2+ patients and higher pCR rates in ER−/HER2+ patients.
In our study pCR rates were similar in black and white women as well as in Hispanics and 
non-Hispanics. Several previous studies have examined the association between race and 
pCR with some finding no difference by race [28,10], while others found lower pCR rates 
among black women.[29,30] Chavez-MacGregor and colleagues found no differences in 
pCR rates between blacks, whites and Hispanics, overall or within tumor subtypes, in a 
retrospective analysis of 2074 patients treated at the M.D. Anderson Cancer Center between 
1994 and 2008, in which the reported pCR rates (overall = 12.5%, HER2+ 22.6%, triple-
negative 19.4%, hormone receptor-positive 5%) were much lower than in our population. 28 
This lower observed pCR rates is at least in part because of differences in pCR definition 
(in-breast vs. breast and axilla) and use of combination therapy (i.e., trastuzumab) in our 
trials. In a more recent paper, Killelea and colleagues, using data from the National Cancer 
Data Base (NCDB), found similar pCR rates across racial groups overall, but when stratified 
by tumor subtype non-Hispanic black women had a non-significantly lower pCR rate for ER
−/HER2+ tumors (42.6% vs. 53.9%; OR: 0.72, 95% CI: 0.46–1.14) and a significantly lower 
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pCR rate for triple-negative (36.6%; 416/1138) tumors (36.6% vs. 42.8%; OR 0.73, 95% CI: 
0.59–0.89) compared to white women [29]. There were no significant differences according 
to Hispanic ethnicity. The different results in the present study and that by Killelea et al. may 
be due to our use of clinical trial populations. The setting of randomized clinical trials 
provides several important advantages including standardized enrollment requirements, 
uniform assessment of disease characteristics such as stage, tumor phenotype and other 
factors associated with prognosis. Treatment is also standardized, carefully monitored, and 
facilitated, eliminating variation in care that may occur outside of a trial. While the NST 
regimen for patients enrolled on Z1071 was not specified in the protocol, most received an 
anthracycline and a taxane in the neoadjuvant setting, and since the treating physicians at the 
participating institutions were familiar with treatment guidelines from other cooperative 
group trials, we considered it highly likely that the treatment plans utilized followed similar 
guidelines (standard chemotherapy dosing using actual rather than ideal body weight to 
calculate body surface area, for example).
Though most of the available data is from the adjuvant setting, there is evidence that black 
women with early stage breast cancer start chemotherapy later, are more likely to receive a 
lower than standard dose and lower relative dose intensity, and are more likely to have dose 
reductions in the first and subsequent treatment cycles compared to whites [31,32]. These 
differences could not be explained by racial differences in BMI, comorbid conditions or 
hematological factors [33]. There is also little evidence of greater levels of acute toxicity in 
black women receiving neoadjuvant or adjuvant chemotherapy [34]. It is possible that the 
lower pCR rates among black women in the NCDB are due to dose reductions, treatment 
delays, or differences in chemotherapy regimens received. Taken together, our results 
suggest that racial differences in pCR identified in retrospective studies may not be caused 
by biology.
Our results suggest that, overall, in-breast pCR rates are not significantly affected by BMI in 
appropriately dosed patients, though there was a non-significant trend towards lower pCR 
rates with a higher BMI (p-trend=0.094). In another retrospective analysis from the M. D. 
Anderson database, Litton and colleagues found that overweight (OR = 0.59, 95% CI: 0.37–
0.95) or the combination of overweight and obese (OR = 0.67, 95% CI: 0.45–0.99) women 
had significantly lower pCR rates compared to normal/underweight women.35 Results were 
not stratified by tumor subtype [35]. Among Chinese women, patients with BMI ≥ 25 kg/m2 
were 55% less likely to achieve pCR compared to those with BMI <25 kg/m2. Differences 
were largest among postmenopausal and HR− patients [36]. Several other studies have 
associated lower BMI with higher rates of pCR [37]. Weight gain during neoadjuvant 
chemotherapy has not been associated with pCR [38], except perhaps in subgroups of 
women who were normal/underweight or postmenopausal at baseline, where it was 
associated with higher pCR rates [39].
In our study, the impact of BMI on pCR appeared to differ by tumor subtype. Specifically, in 
overweight and obese women we saw lower pCR rates in ER+/HER2+ cancers and higher 
pCR rates in ER−/HER2+ cancers. However confidence intervals were wide and it is 
possible that result was due to chance. Potential mechanisms relating overweight and obesity 
to lower pCR rates and poorer survival include: 1) higher circulating estrogen levels among 
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obese postmenopausal women as compared to leaner women and higher estrogen levels 
when on aromatase inhibitor therapy [40], 2) higher levels of circulating insulin, 
adiponectin, c-peptide, leptin and other metabolic hormones [41], and 3) higher circulating 
inflammatory cytokines which may reduce apoptosis and increase proliferation among obese 
women [42,43]. In some settings chemotherapy may not be dosed appropriately leading to 
under dosing of obese women, and this would have a greater impact on black women where 
we observed higher rates of obesity compared to whites [44,45]. Chemotherapy under 
dosing is less of a concern in our clinical trials because weight-based dosing is required 
[26,25,24].
Our study has several important strengths and limitations. While our analysis included 
almost 1800 women, dividing the population by tumor subtype, race, ethnicity and BMI 
limited our statistical power. Our outcome was in-breast pCR (ypT0/Tis), while many other 
studies have used pCR in the breast and axillary nodes (ypT0/Tis ypN0) pCR as their 
endpoint, as it has a stronger association with disease-free survival [46,20]. However, in 
order to explain the difference in results between our study and those using ypT0/Tis ypN0 
race or BMI would have to only affect the likelihood of achieving pCR in the axilla, but not 
in the breast. This seems unlikely since most women that achieve pCR in-breast also do so in 
the axilla [15]. Assigning subtype by ER and HER status alone ignores certain molecular 
heterogeneity within those subtypes that may have a major impact on tumor response and 
achievement of pCR [47,48]. While the treatment regimens received across our included 
trials were not uniform, within each trial with the exception of Z1071, patients received 
standardized therapy. Clinical trial participants may not be representative of the general 
population. For example, clinical trial participants are generally younger than patients in the 
community [49]. Lack of racial and ethnic diversity is problematic in many clinical trials; 
however, our sample was 14% black and 11% Hispanic, reasonably similar to their 
distribution in the United States. Lastly, we did not look at long-term outcomes associated 
with pCR according to race, ethnicity or BMI. Studies that have done this suggest that 
among women that achieve pCR outcomes such as disease-free survival and overall survival 
are similar, but disparities persist among women that do not [28,50]. Further research is 
necessary to tease apart the molecular characteristics and post-neoadjuvant treatment and 
behavioral/environmental exposures that contribute to these disparities among non-
responders.
In conclusion, our study found no differences in breast pCR according to race or Hispanic 
ethnicity and no significant impact of BMI on the overall pCR rate. These findings suggest 
that achievement of pCR with optimally dosed NST is largely a function of tumor, rather 
than patient, biology. It further suggests that yet-to-be-defined biologic factors that may 
influence which patients within each subtype achieve a pCR are also little influenced by 
race, ethnicity and BMI; if these patient characteristics determined those factors we would 
expect to see more substantial differences in the pCR rates among our subgroups. Analysis 
of other studies utilizing similarly effective NST regimens are warranted to see if they also 
demonstrate lower pCR rates in ER+/HER2+ and higher pCR rate in ER−/HER2+ 
overweight and obese women that could generate hypotheses for the etiology of these 
observations.
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Table 3
Pathologic complete response in four Alliance clinical trials according to race, ethnicity and BMI (N=1672)
Na %pCR OR (95% CI)b
Race
 White 1381 550 (39.8) 1.0 (reference)
 Black 245 99 (40.4) 1.18 (0.85, 1.62)
Ethnicity
 Non-Hispanic 1441 570 (39.6) 1.0 (reference)
 Hispanic 194 90 (46.4) 1.22 (0.86, 1.72)
BMI (kg/m2)
 <20 64 33 (51.6) 1.60 (0.89, 2.86)
 20–24 454 198 (43.6) 1.0 (reference)
 25–29 510 198 (38.8) 0.86 (0.64, 1.16)
 ≥30 722 277 (38.4) 0.82 (0.62, 1.08)
 p-trend c 0.094
Subtype
 ER+/HER2− 416 66 (15.9) 1.0 (reference)
 ER+/HER2+ 399 152 (38.1) 2.16 (1.32, 3.51)
 ER−/HER2+ 311 195 (62.7) 5.48 (3.40, 8.85)
 Triple Negative 611 285 (46.6) 2.56 (1.75, 3.75)
a125 women excluded due to missing values of variables;
b
mutually adjusted for all variables in table plus trial arm, tumor grade, lymph node status, tumor size, and subtype;
cp-trend is from a test of linear trend of an ordinal variable defined by the median of each category.
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